The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Clinical Oncology Next Generation Sequencing (NGS)-Global Market Insights and Sales Trends 2024
Synopsis
NGS allows the testing of all types of variants including single-nucleotide variations, insertions, deletions, exon duplications, gene copy number changes and translocations.
The global Clinical Oncology Next Generation Sequencing (NGS) market size is expected to reach US$ 1429.7 million by 2029, growing at a CAGR of 10.6% from 2023 to 2029. The market is mainly driven by the significant applications of Clinical Oncology Next Generation Sequencing (NGS) in various end use industries. The expanding demands from the Academic & Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities,, are propelling Clinical Oncology Next Generation Sequencing (NGS) market. NGS Pre-Sequencing, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Sequencing segment is estimated at % CAGR for the next seven-year period.
The key factor contributing to the growth of the NGS market is the improved understanding of the genetic markers of virulence and resistance.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Clinical Oncology Next Generation Sequencing (NGS), with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Clinical Oncology Next Generation Sequencing (NGS) market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Clinical Oncology Next Generation Sequencing (NGS) market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Clinical Oncology Next Generation Sequencing (NGS) sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Clinical Oncology Next Generation Sequencing (NGS) covered in this report include Illumina, Roche, Agilent Technologies, Knome, Genomatix Software, GATC Biotech, Oxford Nanopore Technologies, Macrogen and Life Technologies, etc.
The global Clinical Oncology Next Generation Sequencing (NGS) market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Illumina
Roche
Agilent Technologies
Knome
Genomatix Software
GATC Biotech
Oxford Nanopore Technologies
Macrogen
Life Technologies
DNASTAR
Exosome Diagnostics
Biomatters
CLC Bio
BGI
Qiagen
Perkin Elmer
Pacific Bioscience
Partek
GnuBIO
Foundation Medicine
Paradigm
Caris Life Sciences
Myriad Genetics
Global Clinical Oncology Next Generation Sequencing (NGS) market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Clinical Oncology Next Generation Sequencing (NGS) market, Segment by Type:
NGS Pre-Sequencing
Sequencing
NGS Data Analysis
Primary, Secondary & Tertiary Data Analysis
Global Clinical Oncology Next Generation Sequencing (NGS) market, by Application
Academic & Clinical Research
Hospitals & Clinics
Pharma & Biotech Entities
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Clinical Oncology Next Generation Sequencing (NGS) companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
NGS allows the testing of all types of variants including single-nucleotide variations, insertions, deletions, exon duplications, gene copy number changes and translocations.
The global Clinical Oncology Next Generation Sequencing (NGS) market size is expected to reach US$ 1429.7 million by 2029, growing at a CAGR of 10.6% from 2023 to 2029. The market is mainly driven by the significant applications of Clinical Oncology Next Generation Sequencing (NGS) in various end use industries. The expanding demands from the Academic & Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities,, are propelling Clinical Oncology Next Generation Sequencing (NGS) market. NGS Pre-Sequencing, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Sequencing segment is estimated at % CAGR for the next seven-year period.
The key factor contributing to the growth of the NGS market is the improved understanding of the genetic markers of virulence and resistance.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Clinical Oncology Next Generation Sequencing (NGS), with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Clinical Oncology Next Generation Sequencing (NGS) market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Clinical Oncology Next Generation Sequencing (NGS) market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Clinical Oncology Next Generation Sequencing (NGS) sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Clinical Oncology Next Generation Sequencing (NGS) covered in this report include Illumina, Roche, Agilent Technologies, Knome, Genomatix Software, GATC Biotech, Oxford Nanopore Technologies, Macrogen and Life Technologies, etc.
The global Clinical Oncology Next Generation Sequencing (NGS) market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Illumina
Roche
Agilent Technologies
Knome
Genomatix Software
GATC Biotech
Oxford Nanopore Technologies
Macrogen
Life Technologies
DNASTAR
Exosome Diagnostics
Biomatters
CLC Bio
BGI
Qiagen
Perkin Elmer
Pacific Bioscience
Partek
GnuBIO
Foundation Medicine
Paradigm
Caris Life Sciences
Myriad Genetics
Global Clinical Oncology Next Generation Sequencing (NGS) market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Clinical Oncology Next Generation Sequencing (NGS) market, Segment by Type:
NGS Pre-Sequencing
Sequencing
NGS Data Analysis
Primary, Secondary & Tertiary Data Analysis
Global Clinical Oncology Next Generation Sequencing (NGS) market, by Application
Academic & Clinical Research
Hospitals & Clinics
Pharma & Biotech Entities
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Clinical Oncology Next Generation Sequencing (NGS) companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Clinical Oncology Next Generation Sequencing (NGS)
1.1 Clinical Oncology Next Generation Sequencing (NGS) Market Overview
1.1.1 Clinical Oncology Next Generation Sequencing (NGS) Product Scope
1.1.2 Clinical Oncology Next Generation Sequencing (NGS) Market Status and Outlook
1.2 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Region (2018-2029)
1.4 Global Clinical Oncology Next Generation Sequencing (NGS) Historic Market Size by Region (2018-2023)
1.5 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Clinical Oncology Next Generation Sequencing (NGS) Market Size (2018-2029)
1.6.1 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size (2018-2029)
1.6.2 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size (2018-2029)
1.6.3 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size (2018-2029)
1.6.4 Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size (2018-2029)
1.6.5 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size (2018-2029)
2 Clinical Oncology Next Generation Sequencing (NGS) Market by Type
2.1 Introduction
2.1.1 NGS Pre-Sequencing
2.1.2 Sequencing
2.1.3 NGS Data Analysis
2.1.4 Primary, Secondary & Tertiary Data Analysis
2.2 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Clinical Oncology Next Generation Sequencing (NGS) Historic Market Size by Type (2018-2023)
2.2.2 Global Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Clinical Oncology Next Generation Sequencing (NGS) Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Clinical Oncology Next Generation Sequencing (NGS) Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Clinical Oncology Next Generation Sequencing (NGS) Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Revenue Breakdown by Type (2018-2029)
3 Clinical Oncology Next Generation Sequencing (NGS) Market Overview by Application
3.1 Introduction
3.1.1 Academic & Clinical Research
3.1.2 Hospitals & Clinics
3.1.3 Pharma & Biotech Entities
3.2 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Clinical Oncology Next Generation Sequencing (NGS) Historic Market Size by Application (2018-2023)
3.2.2 Global Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Clinical Oncology Next Generation Sequencing (NGS) Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Clinical Oncology Next Generation Sequencing (NGS) Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Clinical Oncology Next Generation Sequencing (NGS) Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Revenue Breakdown by Application (2018-2029)
4 Clinical Oncology Next Generation Sequencing (NGS) Competition Analysis by Players
4.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Clinical Oncology Next Generation Sequencing (NGS) as of 2022)
4.3 Date of Key Players Enter into Clinical Oncology Next Generation Sequencing (NGS) Market
4.4 Global Top Players Clinical Oncology Next Generation Sequencing (NGS) Headquarters and Area Served
4.5 Key Players Clinical Oncology Next Generation Sequencing (NGS) Product Solution and Service
4.6 Competitive Status
4.6.1 Clinical Oncology Next Generation Sequencing (NGS) Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Illumina
5.1.1 Illumina Profile
5.1.2 Illumina Main Business
5.1.3 Illumina Clinical Oncology Next Generation Sequencing (NGS) Products, Services and Solutions
5.1.4 Illumina Clinical Oncology Next Generation Sequencing (NGS) Revenue (US$ Million) & (2018-2023)
5.1.5 Illumina Recent Developments
5.2 Roche
5.2.1 Roche Profile
5.2.2 Roche Main Business
5.2.3 Roche Clinical Oncology Next Generation Sequencing (NGS) Products, Services and Solutions
5.2.4 Roche Clinical Oncology Next Generation Sequencing (NGS) Revenue (US$ Million) & (2018-2023)
5.2.5 Roche Recent Developments
5.3 Agilent Technologies
5.3.1 Agilent Technologies Profile
5.3.2 Agilent Technologies Main Business
5.3.3 Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Products, Services and Solutions
5.3.4 Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Revenue (US$ Million) & (2018-2023)
5.3.5 Knome Recent Developments
5.4 Knome
5.4.1 Knome Profile
5.4.2 Knome Main Business
5.4.3 Knome Clinical Oncology Next Generation Sequencing (NGS) Products, Services and Solutions
5.4.4 Knome Clinical Oncology Next Generation Sequencing (NGS) Revenue (US$ Million) & (2018-2023)
5.4.5 Knome Recent Developments
5.5 Genomatix Software
5.5.1 Genomatix Software Profile
5.5.2 Genomatix Software Main Business
5.5.3 Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Products, Services and Solutions
5.5.4 Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Revenue (US$ Million) & (2018-2023)
5.5.5 Genomatix Software Recent Developments
5.6 GATC Biotech
5.6.1 GATC Biotech Profile
5.6.2 GATC Biotech Main Business
5.6.3 GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Products, Services and Solutions
5.6.4 GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Revenue (US$ Million) & (2018-2023)
5.6.5 GATC Biotech Recent Developments
5.7 Oxford Nanopore Technologies
5.7.1 Oxford Nanopore Technologies Profile
5.7.2 Oxford Nanopore Technologies Main Business
5.7.3 Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Products, Services and Solutions
5.7.4 Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Revenue (US$ Million) & (2018-2023)
5.7.5 Oxford Nanopore Technologies Recent Developments
5.8 Macrogen
5.8.1 Macrogen Profile
5.8.2 Macrogen Main Business
5.8.3 Macrogen Clinical Oncology Next Generation Sequencing (NGS) Products, Services and Solutions
5.8.4 Macrogen Clinical Oncology Next Generation Sequencing (NGS) Revenue (US$ Million) & (2018-2023)
5.8.5 Macrogen Recent Developments
5.9 Life Technologies
5.9.1 Life Technologies Profile
5.9.2 Life Technologies Main Business
5.9.3 Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Products, Services and Solutions
5.9.4 Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Revenue (US$ Million) & (2018-2023)
5.9.5 Life Technologies Recent Developments
5.10 DNASTAR
5.10.1 DNASTAR Profile
5.10.2 DNASTAR Main Business
5.10.3 DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Products, Services and Solutions
5.10.4 DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Revenue (US$ Million) & (2018-2023)
5.10.5 DNASTAR Recent Developments
5.11 Exosome Diagnostics
5.11.1 Exosome Diagnostics Profile
5.11.2 Exosome Diagnostics Main Business
5.11.3 Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Products, Services and Solutions
5.11.4 Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Revenue (US$ Million) & (2018-2023)
5.11.5 Exosome Diagnostics Recent Developments
5.12 Biomatters
5.12.1 Biomatters Profile
5.12.2 Biomatters Main Business
5.12.3 Biomatters Clinical Oncology Next Generation Sequencing (NGS) Products, Services and Solutions
5.12.4 Biomatters Clinical Oncology Next Generation Sequencing (NGS) Revenue (US$ Million) & (2018-2023)
5.12.5 Biomatters Recent Developments
5.13 CLC Bio
5.13.1 CLC Bio Profile
5.13.2 CLC Bio Main Business
5.13.3 CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Products, Services and Solutions
5.13.4 CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Revenue (US$ Million) & (2018-2023)
5.13.5 CLC Bio Recent Developments
5.14 BGI
5.14.1 BGI Profile
5.14.2 BGI Main Business
5.14.3 BGI Clinical Oncology Next Generation Sequencing (NGS) Products, Services and Solutions
5.14.4 BGI Clinical Oncology Next Generation Sequencing (NGS) Revenue (US$ Million) & (2018-2023)
5.14.5 BGI Recent Developments
5.15 Qiagen
5.15.1 Qiagen Profile
5.15.2 Qiagen Main Business
5.15.3 Qiagen Clinical Oncology Next Generation Sequencing (NGS) Products, Services and Solutions
5.15.4 Qiagen Clinical Oncology Next Generation Sequencing (NGS) Revenue (US$ Million) & (2018-2023)
5.15.5 Qiagen Recent Developments
5.16 Perkin Elmer
5.16.1 Perkin Elmer Profile
5.16.2 Perkin Elmer Main Business
5.16.3 Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Products, Services and Solutions
5.16.4 Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Revenue (US$ Million) & (2018-2023)
5.16.5 Perkin Elmer Recent Developments
5.17 Pacific Bioscience
5.17.1 Pacific Bioscience Profile
5.17.2 Pacific Bioscience Main Business
5.17.3 Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Products, Services and Solutions
5.17.4 Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Revenue (US$ Million) & (2018-2023)
5.17.5 Pacific Bioscience Recent Developments
5.18 Partek
5.18.1 Partek Profile
5.18.2 Partek Main Business
5.18.3 Partek Clinical Oncology Next Generation Sequencing (NGS) Products, Services and Solutions
5.18.4 Partek Clinical Oncology Next Generation Sequencing (NGS) Revenue (US$ Million) & (2018-2023)
5.18.5 Partek Recent Developments
5.19 GnuBIO
5.19.1 GnuBIO Profile
5.19.2 GnuBIO Main Business
5.19.3 GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Products, Services and Solutions
5.19.4 GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Revenue (US$ Million) & (2018-2023)
5.19.5 GnuBIO Recent Developments
5.20 Foundation Medicine
5.20.1 Foundation Medicine Profile
5.20.2 Foundation Medicine Main Business
5.20.3 Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Products, Services and Solutions
5.20.4 Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Revenue (US$ Million) & (2018-2023)
5.20.5 Foundation Medicine Recent Developments
5.21 Paradigm
5.21.1 Paradigm Profile
5.21.2 Paradigm Main Business
5.21.3 Paradigm Clinical Oncology Next Generation Sequencing (NGS) Products, Services and Solutions
5.21.4 Paradigm Clinical Oncology Next Generation Sequencing (NGS) Revenue (US$ Million) & (2018-2023)
5.21.5 Paradigm Recent Developments
5.22 Caris Life Sciences
5.22.1 Caris Life Sciences Profile
5.22.2 Caris Life Sciences Main Business
5.22.3 Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Products, Services and Solutions
5.22.4 Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Revenue (US$ Million) & (2018-2023)
5.22.5 Caris Life Sciences Recent Developments
5.23 Myriad Genetics
5.23.1 Myriad Genetics Profile
5.23.2 Myriad Genetics Main Business
5.23.3 Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Products, Services and Solutions
5.23.4 Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Revenue (US$ Million) & (2018-2023)
5.23.5 Myriad Genetics Recent Developments
6 North America
6.1 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Clinical Oncology Next Generation Sequencing (NGS) Market Dynamics
11.1 Clinical Oncology Next Generation Sequencing (NGS) Industry Trends
11.2 Clinical Oncology Next Generation Sequencing (NGS) Market Drivers
11.3 Clinical Oncology Next Generation Sequencing (NGS) Market Challenges
11.4 Clinical Oncology Next Generation Sequencing (NGS) Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
